The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Changes & Additions to RISE Measures in 2020

Changes & Additions to RISE Measures in 2020

February 19, 2020 • By From the College

  • Tweet
  • Email
Print-Friendly Version / Save PDF

The ACR reviews and updates measures in the Rheumatology Informatics System for Effectiveness (RISE) each year. The following outlines changes to existing measures and new measures added to RISE for the 2020 calendar year.

You Might Also Like
  • The ACR Advocates for More MIPS Points for RISE Use
  • Research Shows High Adherence to Performance Measures for RA Cohort
  • RISE Readiness for MIPS in 2018
Also By This Author
  • Annual Meeting Preview: Rheumatology Research Foundation Activities

Changes to Existing Measures

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE
  • QPP 177: Rheumatoid Arthritis (RA): Periodic Assessment for Disease Activity
    Measure description: Percentage of patients aged 18 years or older with a diagnosis of RA who have an assessment of disease activity at >50% of encounters of RA for each patient during the measurement year.
    What changed: Patient activity scale (PAS) is no longer endorsed for assessment for RA disease activity. To meet this measure, use one of the following ACR-endorsed RA disease activity measurement tools: SDAI, CDAI, DAS-28, PAS-II or RAPID3.
  • QPP 178: Rheumatoid Arthritis (RA): Functional Status Assessment
    Measure description: Percentage of patients aged 18 years and older with a diagnosis of RA for whom a functional status assessment was performed at least once within 12 months.
    What changed: Acceptable tools for assessing functional status have been narrowed to one of the following ACR-endorsed functional status measurement tools: PROMIS PF10a, HAQ-II or MDHAQ.
  • QPP 180: Rheumatoid Arthritis (RA): Glucocorticoid Management
    Measure description: Percentage of patients aged 18 years and older with a diagnosis of RA who have been assessed for glucocorticoid use and, for those on prolonged doses of prednisone >5 mg daily (or equivalent) with improvement or no change in disease activity, documentation of glucocorticoid management plan within 12 months.
    What changed: The glucocorticoid dose threshold for prolonged use was reduced from prednisone >10 mg to >5 mg daily (or equivalent).
  • ACR14 (previously ACR7): Gout: Serum Urate Target
    Measure description: Percentage of patients aged 18 or older with a diagnosis of gout treated with urate-lowering therapy (ULT) for at least 12 months, whose most recent serum urate result is less than 6.0 mg/dL.
    What changed: The serum urate target was reduced from less than 6.8 mg/dL to less than 6.0 mg/dL.

New Measures in 2020
The new measures in RISE are meant offer our providers a wider breadth of rheumatology-specific measures to assess their quality of care. The new measures for 2020 expand the opportunity for rheumatologists to find measures meaningful to their practice and patients. The specifications for each of the new measures are available on the registry website.

  • ACR9: Rheumatoid Arthritis Patients with Low Disease Activity or Remission
    Measure description: The proportion of individuals with RA who have low disease activity or are in remission based on the last recorded disease activity score in the measurement year.
    Measure type: Intermediate Outcome, High Priority
  • ACR10: Hepatitis B Safety Screening
    Measure description: If a patient is newly initiating biologic or new synthetic disease-modifying antirheumatic drug (DMARD) therapy, the medical record should indicate appropriate screening for hepatitis B in the preceding 12-month period.Measure type: Process, High Priority
  • ACR11: Hydroxychloroquine Dosing
    Measure description: If a patient is using hydroxychloroquine, the average daily dose should be <6.5 mg/kg.
    Measure type: Process, High Priority
  • ACR12: Disease Activity Measurement for Patients with Psoriatic Arthritis
    Measure description: If a patient has psoriatic arthritis (PsA), disease activity using a standardized measurement tool should be assessed at >50% of encounters for PsA.
    Measure type: Process
  • ACR13: Tuberculosis Test Prior to First Course Biologic Therapy
    Measure description: If a patient has been newly prescribed a biologic therapy, then the medical record should indicate TB testing in the preceding 12-month period.
    Measure type: Process, High Priority

For questions or more details on these changes and new measures, email RISE@rheumatology.org.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Pages: 1 2 | Single Page

Filed Under: Practice Management Tagged With: Rheumatology Informatics System for Effectiveness (RISE) Registry

You Might Also Like:
  • The ACR Advocates for More MIPS Points for RISE Use
  • Research Shows High Adherence to Performance Measures for RA Cohort
  • RISE Readiness for MIPS in 2018
  • Quality Measures Used to Assess Care, Improve Outcomes in Children, Adults with Rheumatic Diseases

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.